Can you stop taking Wegovy at any time — and what happens when you do?

What the STEP trial data shows about regaining weight after stopping

The clearest evidence comes from the STEP 1 extension study, published in the journal Diabetes, Obesity and Metabolism. Participants who had lost an average of around 15% of body weight over 68 weeks on semaglutide 2.4mg were observed for a further 52 weeks after stopping. Within that year, they regained roughly two-thirds of what they had lost. Appetite returned, calorie intake increased, and the metabolic adaptations the medicine had produced gradually unwound.

This is not a sign the drug had failed. Weight loss on Wegovy follows a predictable curve that reflects active pharmacological suppression of appetite, and when the suppression lifts, the underlying biology reasserts itself. The brain's hunger signals, slowed gastric emptying, and the sense of fullness that semaglutide produces: all of those return to baseline. The medicine treats the condition; it does not cure it. That is exactly what a chronic disease framework predicts, and it is the same reasoning behind the two-year NICE recommendation.

A common misconception worth naming gently here is the idea that weight regain means the treatment never really worked. It does not mean that. It means obesity is a long-term condition (one shaped by biology, not willpower) and that the treatment needs to be sustained to sustain the results. The timeline of Wegovy's effects is relevant context: peak results typically appear at around 60–68 weeks, and they depend on the medicine remaining active.

For the science behind this, the NHS's clinical summary of semaglutide sets out how the medicine works and what stopping means in plain terms.

Why stopping can feel abrupt even when you taper

Wegovy has a half-life of around a week, so its effects do fade gradually rather than overnight. Even so, people often report that hunger returns faster and more intensely than they expected. This surprises patients who assumed the lifestyle changes they had built during treatment would carry them through. Sometimes they do. More often, the appetite signals that semaglutide had been quietly dampening reassert themselves before those habits are fully embedded.

There is also a practical dimension. Stopping semaglutide is not dangerous in itself, and there are no serious withdrawal symptoms in the pharmacological sense. What is real, though, is the return of the physiological drive to eat more. Some people find this manageable; others find the transition genuinely difficult. How well-established their diet and activity habits are, whether they have ongoing support, and where they are in the treatment course all influence the experience.

The NICE guidance on semaglutide (TA875) includes a review point at six months: if a patient has not achieved at least 5% weight loss at the maintenance dose, continuing is unlikely to be in their interest. That is a formal, evidence-based stopping criterion, distinct from stopping because things are going well. When stopping Wegovy makes clinical sense is a broader question that depends on which of these situations applies to you.

Having the stopping conversation with a prescriber

The question of whether to stop, and how, is one where a prescriber's input matters more than most people realise before they ask it. The answer is different depending on whether you are stopping because you have reached your target weight and feel ready, because of side effects, because of cost, because the medicine is not working, or because you are planning a pregnancy.

Pregnancy and breastfeeding are clear contraindications, semaglutide should not be used during pregnancy, and MHRA guidance recommends stopping and using effective contraception during treatment, with appropriate time before trying to conceive. That is a non-negotiable stopping reason, and it is one to discuss in advance. For contraception considerations while on treatment, NHS England's guidance on weight-management injections covers the practical steps.

For people stopping for other reasons, a prescriber can also talk through what realistic expectations look like for the months ahead. Stopping Wegovy after reaching your target weight is a specific scenario with its own evidence base. There are also questions about whether switching to a lower maintenance dose, or stepping down gradually, might achieve a better outcome than stopping abruptly. A structured approach to discontinuing Wegovy exists, and it is worth exploring.

At nume, the clinical team reviews every repeat order before it is dispensed, so a conversation about whether to continue, adjust or stop is always available. If you would like that conversation before your next supply, speak to our prescribers through a free consultation.